TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Executive Column: HKEX eyes RI’s biotech, digital firms for Hong Kong listing
According to HKEX CEO Nicolas Aguzin, digital start-ups, biotech companies and firms wishing to go international should look to Hong Kong for their IPOs.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Nicolas Aguzin, CEO of Hong Kong Exchanges and Clearing Limited (HKEX), on July 26 during his visit to Jakarta. (JP/Aditya Hadi/JP/Aditya Hadi)
T
he Indonesia Stock Exchange (IDX) is considered one of the most active IPO markets in Southeast Asia and the fourth most active in the world, according to a recent study from advisory firm EY.
Several international stock exchanges are eyeing IDX as a promising partner, including Hong Kong Exchanges and Clearing Limited (HKEX).
HKEX CEO Nicolas Aguzin spoke to The Jakarta Post's Aditya Hadi in Jakarta on July 26 about potential collaboration with IDX, the opportunity for local companies to be listed on the Hong Kong Stock Exchange and the future of special purpose acquisition companies (SPACs).
Question: How do you see Indonesia and the local stock exchange (IDX)?
Answer: I think it's an evolving, up and coming market. We clearly look at what's happening this year, including a lot of transactions that happened. It reflects what's going on in the country and the growth of the local ecosystem.
Particularly, when it comes to innovation, with all of the new unicorn [start-ups] that you're seeing in Indonesia.
Recently, HKEX has signed a memorandum of understanding (MOU) with IDX. Could you explain the content of the agreement?
